Skip to main content

Advertisement

SpringerLink
Log in

The new puzzle about the treatment of type 2 diabetes after the ACCORD and Da Qing studies

  • Review Article
  • Published:
Langenbeck's Archives of Surgery Aims and scope Submit manuscript

Abstract

Introduction

There is a dramatic increase in the worldwide incidence of obesity, diabetes mellitus type 2, and other cardiovascular risk factors, summarized previously under the term "metabolic syndrome". Although preventive lifestyle modifications are effective, they are hard to implement and are therefore associated with a high number needed to treat. In most cases, intervention studies with hard endpoints such as myocardial infarction, stroke, or death are missing.

Results

For example, the Da Qing study proved the efficacy of lifestyle modification with respect to manifestation of diabetes, but failed to show clear benefits regarding cardiovascular mortality. Several studies raised doubt, whether the concept of optimally reducing glucose is the optimal treatment for improving cardiovascular endpoints. Moreover other studies, such as Steno-2, showed an impressive effect of a multimodal therapy on hard endpoints.

Conclusions

In the future, the focus on new strategies for individualized therapies will increase. Additionally, approaches targeting novel molecular pathways are on the horizon, since plasma levels of posttranslationally modified proteins such as HbA1c are strong cardiovascular risk predictors despite normal glucose levels. For the clinician, it now becomes obvious that epidemiologically proven associations do not necessarily reflect causality. Studies addressing defined clinical endpoints, such as micro- and macrovascular morbidity and mortality are needed, as well as basic research, investigating other pathophysiological mechanisms, e.g., reactive metabolites and the digestive tract. The unexplained reduction in diabetes and its complications by bariatric surgery will give further insight not only into new therapeutic approaches, but also into mechanisms yet to be discovered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC (1994) Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 17(9):961–969

    Article  PubMed  CAS  Google Scholar 

  2. Colditz GA, Willett WC, Rotnitzky A, Manson JE (1995) Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 122(7):481–486

    PubMed  CAS  Google Scholar 

  3. Marroquin OC, Kip KE, Kelley DE, Johnson BD, Shaw LJ, Bairey Merz CN, Sharaf BL, Pepine CJ, Sopko G, Reis SE (2004) Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the women’s ischemia syndrome evaluation. Circulation 109(6):714–721. doi:10.1161/01.CIR.0000115517.26897.A7

    Article  PubMed  CAS  Google Scholar 

  4. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, Howard BV (2003) Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the strong heart study. Diabetes Care 26(3):861–867

    Article  PubMed  Google Scholar 

  5. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438):937–952. doi:10.1016/S0140-6736(04)17018-9

    Article  PubMed  Google Scholar 

  6. von Lengerke T, Hagenmeyer EG, Gothe H, Schiffhorst G, Happich M, Haussler B (2010) Excess health care costs of obesity in adults with diabetes mellitus: a claims data analysis. Exp Clin Endocrinol Diabetes 118(8):496–504. doi:10.1055/s-0030-1253400

    Article  Google Scholar 

  7. Colditz GA, Willett WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA, Speizer FE (1990) Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 132(3):501–513

    PubMed  CAS  Google Scholar 

  8. Fogelholm M (2010) Physical activity, fitness and fatness: relations to mortality, morbidity and disease risk factors. A systematic review. Obes Rev 11(3):202–221. doi:10.1111/j.1467-789X.2009.00653.x

    Article  PubMed  CAS  Google Scholar 

  9. Pataky Z, Bobbioni-Harsch E, Golay A (2010) Obesity: a complex growing challenge. Exp Clin Endocrinol Diabetes 118(7):427–433. doi:10.1055/s-0029-1233448

    Article  PubMed  CAS  Google Scholar 

  10. Berrington deGonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL, English DR, Folsom AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman-Bolton J, Hoppin JA, Koenig KL, Lee IM, Linet MS, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jacquotte A, Willett WC, Thun MJ (2010) Body-mass index and mortality among 1.46 million white adults. N Engl J Med 363(23):2211–2219. doi:10.1056/NEJMoa1000367

    Article  CAS  Google Scholar 

  11. Shimazu T, Kuriyama S, Ohmori-Matsuda K, Kikuchi N, Nakaya N, Tsuji I (2009) Increase in body mass index category since age 20 years and all-cause mortality: a prospective cohort study (the Ohsaki Study). Int J Obes (Lond) 33(4):490–496. doi:10.1038/ijo.2009.29

    Article  CAS  Google Scholar 

  12. Muckelbauer R, Libuda L, Clausen K, Reinehr T, Kersting M (2009) A simple dietary intervention in the school setting decreased incidence of overweight in children. Obes Facts 2(5):282–285. doi:10.1159/000229783

    Article  PubMed  Google Scholar 

  13. Harrington M, Gibson S, Cottrell RC (2009) A review and meta-analysis of the effect of weight loss on all-cause mortality risk. Nutr Res Rev 22(1):93–108. doi:10.1017/S0954422409990035

    Article  PubMed  Google Scholar 

  14. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ (2005) Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 353(20):2111–2120. doi:10.1056/NEJMoa050156

    Article  PubMed  CAS  Google Scholar 

  15. Fujioka K, Lee MW (2007) Pharmacologic treatment options for obesity: current and potential medications. Nutr Clin Pract 22(1):50–54

    Article  PubMed  Google Scholar 

  16. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, Lamonte MJ, Stroup AM, Hunt SC (2007) Long-term mortality after gastric bypass surgery. N Engl J Med 357(8):753–761. doi:10.1056/NEJMoa066603

    Article  PubMed  CAS  Google Scholar 

  17. Al Snih S, Ottenbacher KJ, Markides KS, Kuo YF, Eschbach K, Goodwin JS (2007) The effect of obesity on disability vs mortality in older Americans. Arch Intern Med 167(8):774–780. doi:10.1001/archinte.167.8.774

    Article  PubMed  Google Scholar 

  18. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R (2009) Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373(9669):1083–1096. doi:10.1016/S0140-6736(09)60318-4

    Article  PubMed  Google Scholar 

  19. Siebenhofer A, Horvath K, Jeitler K, Berghold A, Stich AK, Matyas E, Pignitter N, Siering U (2009) Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev. doi:10.1002/14651858, (3):CD007654

    PubMed  Google Scholar 

  20. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363(10):905–917. doi:10.1056/NEJMoa1003114

    Article  PubMed  CAS  Google Scholar 

  21. Huffman DM (2010) Exercise as a calorie restriction mimetic: implications for improving healthy aging and longevity. Interdiscip Top Gerontol 37:157–174. doi:10.1159/000320000

    Article  PubMed  Google Scholar 

  22. Greco D, Pisciotta M, Gambina F, Maggio F (2010) Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older. Exp Clin Endocrinol Diabetes 118(4):215–219. doi:10.1055/s-0029-1241823

    Article  PubMed  CAS  Google Scholar 

  23. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, Prina Cerai S, Pagano G, Cavallo-Perin P (2004) Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the casale monferrato study. Diabetes Care 27(11):2689–2694

    Article  PubMed  Google Scholar 

  24. Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal: joint statement from the American diabetes association and the European association for the Study of diabetes. Diabetes Care 28(9):2289–2304

    Article  PubMed  Google Scholar 

  25. Haring R, Wallaschofski H, Nauck M, Felix SB, Schmidt CO, Dorr M, Sauer S, Wilmking G, Volzke H (2010) Total and cardiovascular disease mortality predicted by metabolic syndrome is inferior relative to its components. Exp Clin Endocrinol Diabetes 118(10):685–691. doi:10.1055/s-0030-1261876

    Article  PubMed  CAS  Google Scholar 

  26. Borch-Johnsen K, Wareham N (2010) The rise and fall of the metabolic syndrome. Diabetologia 53(4):597–599. doi:10.1007/s00125-010-1659-2

    Article  PubMed  CAS  Google Scholar 

  27. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR (2009) Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373(9682):2215–2221. doi:10.1016/S0140-6736(09)60619-X

    Article  PubMed  CAS  Google Scholar 

  28. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH (2008) The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing diabetes prevention study: a 20-year follow-up study. Lancet 371(9626):1783–1789. doi:10.1016/S0140-6736(08)60766-7

    Article  PubMed  Google Scholar 

  29. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344(18):1343–1350. doi:10.1056/NEJM200105033441801

    Article  PubMed  CAS  Google Scholar 

  30. Hippisley-Cox J, Coupland C, Robson J, Sheikh A, Brindle P (2009) Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ 338:b880

    Article  PubMed  Google Scholar 

  31. Schulze MB, Hoffmann K, Boeing H, Linseisen J, Rohrmann S, Mohlig M, Pfeiffer AF, Spranger J, Thamer C, Haring HU, Fritsche A, Joost HG (2007) An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care 30(3):510–515. doi:10.2337/dc06-2089

    Article  PubMed  Google Scholar 

  32. Tuomilehto J, Lindstrom J, Hellmich M, Lehmacher W, Westermeier T, Evers T, Bruckner A, Peltonen M, Qiao Q, Chiasson JL (2010) Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score. Diabet Res Clin Pract 87(2):267–274. doi:10.1016/j.diabres.2009.11.011

    Article  CAS  Google Scholar 

  33. Sattar N, Wannamethee SG, Forouhi NG (2008) Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia 51(6):926–940. doi:10.1007/s00125-008-0954-7

    Article  PubMed  CAS  Google Scholar 

  34. ADA (2011) Standards of medical care in diabetes–2011. Diabetes Care 34(Suppl 1):S11–S61. doi:10.2337/dc11-S011

    Google Scholar 

  35. Pi-Sunyer FX (2002) Type 2 diabetes outcomes. Obes Res 10(Suppl 1):22S–26S. doi:10.1038/oby.2002.185

    Article  PubMed  Google Scholar 

  36. Dixon JB, O’Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, Bailey M, Anderson M (2008) Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299(3):316–323. doi:10.1001/jama.299.3.316

    Article  PubMed  CAS  Google Scholar 

  37. DeFronzo RA, Goodman AM (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The multicenter metformin study group. N Engl J Med 333(9):541–549. doi:10.1056/NEJM199508313330902

    Article  PubMed  CAS  Google Scholar 

  38. Monnier L, Colette C (2009) Target for glycemic control: concentrating on glucose. Diabetes Care 32(Suppl 2):S199–S204. doi:10.2337/dc09-S310

    Article  PubMed  CAS  Google Scholar 

  39. Schutt M, Kern W, Zimmermann A, Busch P, Kerner W, Voll A, Wagner C, Kann PH, Dapp A, Holl RW (2010) Association of antidiabetic therapies to glycemic control and to body weight in type 2 diabetes: a German multicenter analysis on 9294 patients. Exp Clin Endocrinol Diabetes 118(8):490–495. doi:10.1055/s-0030-1249024

    Article  PubMed  CAS  Google Scholar 

  40. Tone A, Iseda I, Higuchi C, Tsukamoto K, Katayama A, Matsushita Y, Hida K, Wada J, Shikata K (2010) Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes. Exp Clin Endocrinol Diabetes 118(5):320–324. doi:10.1055/s-0029-1243230

    Article  PubMed  CAS  Google Scholar 

  41. Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358(6):580–591. doi:10.1056/NEJMoa0706245

    Article  PubMed  CAS  Google Scholar 

  42. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560–2572. doi:10.1056/NEJMoa0802987

    Article  PubMed  CAS  Google Scholar 

  43. UKPDS-Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352(9131):837–853

    Article  Google Scholar 

  44. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359(15):1577–1589. doi:10.1056/NEJMoa0806470

    Article  PubMed  CAS  Google Scholar 

  45. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545–2559. doi:10.1056/NEJMoa0802743

    Article  PubMed  CAS  Google Scholar 

  46. Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, Uusitupa M, Tuomilehto J (2003) The finnish diabetes prevention study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 26(12):3230–3236

    Article  PubMed  Google Scholar 

  47. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393–403. doi:10.1056/NEJMoa012512

    Article  PubMed  CAS  Google Scholar 

  48. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16(2):434–444

    Article  PubMed  CAS  Google Scholar 

  49. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N (2001) Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 322(7277):15–18

    Article  PubMed  CAS  Google Scholar 

  50. Skriver MV, Borch-Johnsen K, Lauritzen T, Sandbaek A (2010) HbA1c as predictor of all-cause mortality in individuals at high risk of diabetes with normal glucose tolerance, identified by screening: a follow-up study of the Anglo-Danish-Dutch study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION), Denmark. Diabetologia 53(11):2328–2333. doi:10.1007/s00125-010-1867-9

    Article  PubMed  CAS  Google Scholar 

  51. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 362(9):800–811. doi:10.1056/NEJMoa0908359

    Article  PubMed  CAS  Google Scholar 

  52. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290(4):486–494. doi:10.1001/jama.290.4.486

    Article  PubMed  CAS  Google Scholar 

  53. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care 20(4):537–544

    Article  PubMed  CAS  Google Scholar 

  54. Ceriello A, Ihnat MA, Thorpe JE (2009) Clinical review 2: the “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 94(2):410–415. doi:10.1210/jc.2008-1824

    Article  PubMed  CAS  Google Scholar 

  55. Ahmed N, Thornalley PJ (2007) Advanced glycation endproducts: what is their relevance to diabetic complications? Diabet Obes Metab 9(3):233–245. doi:10.1111/j.1463-1326.2006.00595.x

    Article  CAS  Google Scholar 

  56. Kankova K, Benes P, Kuchrickova S (2010) Functional analysis of the common haplotype in the receptor for advanced glycation end-products gene previously identified as a susceptibility factor for diabetic nephropathy. Exp Clin Endocrinol Diabetes 118(2):93–95. doi:10.1055/s-0029-1241198

    Article  PubMed  CAS  Google Scholar 

  57. Bierhaus A, Nawroth PP (2009) Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 52(11):2251–2263. doi:10.1007/s00125-009-1458-9

    Article  PubMed  CAS  Google Scholar 

  58. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmee E, Cousin B, Sulpice T, Chamontin B, Ferrieres J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56(7):1761–1772. doi:10.2337/db06-1491

    Article  PubMed  CAS  Google Scholar 

  59. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57(6):1470–1481. doi:10.2337/db07-1403

    Article  PubMed  CAS  Google Scholar 

  60. Eshraghian A, Hashemi SA, Hamidian Jahromi A, Eshraghian H, Masoompour SM, Davarpanah MA, Eshraghian K, Taghavi SA (2009) Helicobacter pylori infection as a risk factor for insulin resistance. Dig Dis Sci 54(9):1966–1970. doi:10.1007/s10620-008-0557-7

    Article  PubMed  Google Scholar 

  61. Gen R, Demir M, Ataseven H (2010) Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. South Med J 103(3):190–196. doi:10.1097/SMJ.0b013e3181cf373f

    Article  PubMed  Google Scholar 

  62. Ojetti V, Pitocco D, Bartolozzi F, Danese S, Migneco A, Lupascu A, Pola P, Ghirlanda G, Gasbarrini G, Gasbarrini A (2002) High rate of Helicobacter pylori re-infection in patients affected by type 1 diabetes. Diabetes Care 25(8):1485

    Article  PubMed  Google Scholar 

  63. Imai J, Yamada T, Saito T, Ishigaki Y, Hinokio Y, Kotake H, Oka Y, Katagiri H (2009) Eradication of insulin resistance. Lancet 374(9685):264. doi:10.1016/S0140-6736(09)60872-2

    Article  PubMed  Google Scholar 

  64. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P (2010) Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 107(33):14691–14696. doi:10.1073/pnas.1005963107

    Article  PubMed  Google Scholar 

  65. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I (2009) Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122(3):248–256. doi:10.1016/j.amjmed.2008.09.041, e245

    Article  PubMed  Google Scholar 

  66. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351(26):2683–2693. doi:10.1056/NEJMoa035622

    Article  PubMed  Google Scholar 

  67. DePaula AL, Macedo AL, Mota BR, Schraibman V (2009) Laparoscopic ileal interposition associated to a diverted sleeve gastrectomy is an effective operation for the treatment of type 2 diabetes mellitus patients with BMI 21–29. Surg Endosc 23(6):1313–1320. doi:10.1007/s00464-008-0156-x

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

M.P. is supported by the postdoctoral fellowship program of the medical faculty of Heidelberg.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Medizinische Universitätsklinik, Abteilung Innere Medizin 1 und Klinische Chemie, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany

    Michael Pfeiffer, Rüdiger von Bauer & Peter P. Nawroth

Authors
  1. Michael Pfeiffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rüdiger von Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter P. Nawroth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter P. Nawroth.

Additional information

Michael Pfeiffer and Rüdiger von Bauer contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pfeiffer, M., von Bauer, R. & Nawroth, P.P. The new puzzle about the treatment of type 2 diabetes after the ACCORD and Da Qing studies. Langenbecks Arch Surg 396, 941–947 (2011). https://doi.org/10.1007/s00423-011-0781-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00423-011-0781-z

Keywords

Search

Navigation